Apparently the unique vaccine against HIV will soon be launched on the market
According "Remedium", Inovio company is close to creating an effective DNA vaccine Pennvax-GP against HIV infection. Clinical studies of the first phase have already been published.
Scientists tested the vaccine alone with interleukin-12 (IL-12 - an activator of cellular immunity). This combination produced a cellular immune response and increased expression of CD4 + or CD8 + cells in 71 of 76 patients. That is, the vaccine efficacy was 93%. But the humoral immune response (activation of B cells) was recorded in 94% of volunteers.
Human trials are conducted by the developers with the support of the National Institute of Allergy and Infectious Diseases USA (NIAID). By the way, NIAID organized field researches of a special immunization course against HIV infection. In South Africa 5,400 people participated in the experiment.
Two experimental vaccines - ALVAC-HIV (vector vaccine) and a two-component subunit vaccine based on the gp120 virus protein are used. Plus, the volunteers were injected with a vaccine enhancer.